Nanotherapeutics Acquires Two Late Stage Clinical Programs For Alzheimer’s Treatment And CDA Disease

Nanotherapeutics, Inc., a privately held biopharmaceutical company, announced that it has acquired in bankruptcy proceedings two late stage clinical programs: Ramoplanin from Oscient Pharmaceuticals Corporation and PRX-3140 from EPIX Pharmaceuticals, Inc. Ramoplanin - an oral antibiotic for the treatment of Clostridium difficile-associated disease (CDAD) - is entering Phase 3 trials...

DISCLAIMER: Warning! Warning! We are NOT medical doctors and don't even play them on TV. We're just ordinary people reporting on health developments as we hear about them. None of the statements on this website has been evaluated by the FDA. Furthermore, none of the statements on this website should be construed as dispensing medical advice or making claims regarding the cure of diseases. You should always consult a licensed health care professional before starting any supplement, dietary, or exercise program, especially if you are pregnant or have any pre-existing injuries or medical conditions. FURTHERMORE: If you purchase any product through our emails or via this website, we may earn a sales commission. We review and promote products about natural health... so we definitely have a conflict of interest. Any results we tell you about are DEFINITELY not typical and we can't guarantee that any product you find through our website or emails will make a damn bit of difference in your life... so, buyer beware! In fact, many products do not work at all! You could waste hundreds of dollars on products and not see a single change in your health. Sorry, but that's just the reality. Read the promos we tell you about and make up your own mind. No promises and definitely no guarantees!

Comments are closed.